Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Katsuyuki HottaMitsune Tanimoto

Abstract

Data comparing the incidence and pattern of interstitial lung disease (ILD) in non-small cell lung cancer patients receiving treatment with gefitinib versus erlotinib, both of which are epidermal growth factor receptor tyrosine kinase inhibitors, are scarce. We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib. We reviewed the clinical records of 209 patients treated with erlotinib in 2008 (cohort A) and 330 treated with gefitinib between 2000 and 2003 (cohort B). Toxicity within the first month of treatment was investigated. The patients in cohort A had fewer known risk factors for ILD (e.g., poor performance status and prior pulmonary fibrosis). ILD was detected in two patients (1.0%) from cohort A and eight patients (2.4%) from cohort B during the first month of treatment. The events were graded as follows: one patient each in grades 1 and 2 (cohort A), and one, one, and six patients in grades 3, 4, and 5, respectively (cohort B). Multivariate analysis revealed that poor performance status and prior pulmonary fibrosis were significantly correlated with the occurrence of ILD, but the type of epidermal growth factor receptor tyrosine kinase inhibitor administered was not. There was a so...Continue Reading

References

Jan 18, 2003·Lancet·Akira InoueToshihiro Nukiwa
Jun 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Toshimi TakanoNagahiro Saijo
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Román Pérez-SolerPhilip Bonomi
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 13, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Katsuyuki HottaMitsune Tanimoto
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiko AndoMasahiro Fukuoka
Sep 18, 2007·Chest·Vincent LiuChristopher G Azzoli
Dec 6, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kaoru KubotaNagahiro Saijo
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Glenwood GossAlison A Armour
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R GandaraPhilip C Mack

❮ Previous
Next ❯

Citations

Jul 4, 2012·International Journal of Clinical Oncology·Yuka Horiuchi-YamamotoShoji Kudoh
Dec 22, 2004·Current Treatment Options in Oncology·Ariel Birnbaum, Neal Ready
Feb 16, 2013·Japanese Journal of Clinical Oncology·Shinji NakamichiTomohide Tamura
Jan 18, 2013·The Keio Journal of Medicine·Yasunari Takada, Koichi Matsuo
Oct 27, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Stephanie-Jayne Jones, Tsveta Milenkova
Mar 13, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Seung-Hoon BeomDae Seog Heo
May 15, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yosuke TogashiMichiaki Mishima
Nov 22, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·R ter HeineJ J G van den Brand
Dec 18, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Liang ShiZhe Liu
Jan 1, 2015·Clinical Lung Cancer·Cristina BugésRafael Rosell
Sep 30, 2016·Cancer Science·Kan YonemoriNaoko Takebe
Jan 8, 2015·The Annals of Pharmacotherapy·Takumi SakuradaKeisuke Ishizawa
Mar 16, 2017·International Journal of Cancer. Journal International Du Cancer·Zuyao YangJinling Tang
Jul 8, 2011·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Kimberly J GordenJill M Kolesar
Nov 16, 2017·International Journal of Molecular Sciences·Toshimitsu YamaokaTohru Ohmori
Apr 7, 2019·International Journal of Clinical Oncology·Kazuo TamuraYoichi Nakanishi
Aug 3, 2011·Expert Review of Anticancer Therapy·Katsuyuki Hotta, Katsuyuki Kiura
Jul 31, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Kathryn Long, Karthik Suresh
Feb 2, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Fusao Komada
Mar 9, 2019·International Journal of Clinical Oncology·Satoru SenooKatsuyuki Kiura
Mar 29, 2014·Experimental and Therapeutic Medicine·Changqin LuoJin Yang
Aug 24, 2017·Journal of Thoracic Imaging·Girish S ShroffMylene T Truong
Nov 18, 2018·International Journal of Molecular Sciences·Akira SaitoTakahide Nagase
Nov 2, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Takumi Sakurada

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.